Cazzagon Nora, El Mouhadi Sanaâ, Vanderbecq Quentin, Ferreira Carlos, Finnegan Sarah, Lemoinne Sara, Corpechot Christophe, Chazouillères Olivier, Arrivé Lionel
Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Department of Hepatology, Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis (CRMR MIVB-H), ERN RARE-LIVER, Saint-Antoine Hospital, Paris, France.
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.
JHEP Rep. 2022 Sep 3;4(11):100577. doi: 10.1016/j.jhepr.2022.100577. eCollection 2022 Nov.
BACKGROUND & AIMS: People with primary sclerosing cholangitis (PSC) have a variable and often progressive disease course that is associated with biliary and parenchymal changes. These changes are typically assessed by magnetic resonance imaging (MRI), including qualitative assessment of magnetic resonance cholangiopancreatography (MRCP). Our aim was to study the association of novel objective quantitative MRCP metrics with prognostic scores and patient outcomes.
We performed a retrospective study including 77 individuals with large-duct PSC with baseline MRCP images, which were postprocessed to obtain quantitative measures of bile ducts using MRCP+™. The participants' ANALI scores, liver stiffness by vibration-controlled transient elastography, and biochemical indices were collected at baseline. Adverse outcome-free survival was measured as the absence of decompensated cirrhosis, liver transplantation (LT), or liver-related death over a 12-year period. The prognostic value of MRCP+-derived metrics was assessed by Cox regression modelling.
During a total of 386 patients-years, 16 cases of decompensation, 2 LTs, and 5 liver-related deaths were recorded. At baseline, around 50% of the patients were classified as being at risk of developing disease complications. MRCP+ metrics, particularly those describing the severity of bile duct dilatations, were correlated with all prognostic factors. Univariate analysis showed that MRCP+ metrics representing duct diameter, dilatations, and the percentage of ducts with strictures and/or dilatations were associated with survival. In a multivariable-adjusted analysis, the median duct diameter was significantly associated with survival (hazard ratio 10.9, 95% CI 1.3-90.3).
MRCP+ metrics in people with PSC correlate with biochemical, elastographic, and radiological prognostic scores and are predictive of adverse outcome-free survival.
In this study, we assessed in people with primary sclerosing cholangitis (PSC) the association of novel objective quantitative MRCP metrics automatically provided by a software tool (MRCP+) with prognostic scores and patient outcomes. We observed that MRCP+ metrics in people with PSC correlate with biochemical, elastographic, and radiological prognostic scores and are predictive of adverse outcome-free survival.
原发性硬化性胆管炎(PSC)患者的病程多变且常呈进行性发展,与胆管及实质改变相关。这些改变通常通过磁共振成像(MRI)进行评估,包括磁共振胰胆管造影(MRCP)的定性评估。我们的目的是研究新型客观定量MRCP指标与预后评分及患者结局之间的关联。
我们进行了一项回顾性研究,纳入77例患有大胆管PSC且有基线MRCP图像的个体,使用MRCP+™对图像进行后处理以获取胆管的定量测量值。在基线时收集参与者的ANALI评分、通过振动控制瞬时弹性成像测量的肝脏硬度以及生化指标。将无不良结局生存期定义为在12年期间未出现失代偿性肝硬化、肝移植(LT)或肝脏相关死亡。通过Cox回归模型评估MRCP+衍生指标的预后价值。
在总共386患者年中,记录到16例失代偿、2例肝移植和5例肝脏相关死亡。在基线时,约50%的患者被归类为有发生疾病并发症的风险。MRCP+指标,特别是那些描述胆管扩张严重程度的指标,与所有预后因素相关。单因素分析显示,代表导管直径、扩张以及有狭窄和/或扩张的导管百分比的MRCP+指标与生存率相关。在多变量调整分析中,中位导管直径与生存率显著相关(风险比10.9,95%置信区间1.3 - 90.3)。
PSC患者的MRCP+指标与生化、弹性成像和放射学预后评分相关,并可预测无不良结局生存期。
在本研究中,我们评估了原发性硬化性胆管炎(PSC)患者中由软件工具(MRCP+)自动提供的新型客观定量MRCP指标与预后评分及患者结局之间的关联。我们观察到,PSC患者的MRCP+指标与生化、弹性成像和放射学预后评分相关,并可预测无不良结局生存期。